Results 191 to 200 of about 25,216 (236)

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer. [PDF]

J Transl Med
Greiner SM, Mauermann J, Lutz MS, Hagelstein I, Hartkopf AD, Zekri L, Jung G, Salih HR, Märklin M.   +8 more
europepmc   +1 more source

Comparative efficacy and safety of bispecific antibody teclistamab versus CAR-T cell therapies in relapsed/refractory multiple myeloma: a retrospective evaluation. [PDF]

Am J Cancer Res
Guo Y, Shi R.
europepmc   +1 more source

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A

Haemophilia, Volume 32, Issue 2, Page 402-409, March/April 2026.
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E. Croteau   +3 more
wiley   +1 more source

A bispecific antibody targeting PD-L1/TNFR2 increases tumor targeting and enhances antitumor efficacy in colorectal cancer. [PDF]

J Immunother Cancer
Kang X, Qian P, Han Y, Wu M, Li Y, Xu C, Wei J.   +6 more
europepmc   +1 more source

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis

Haemophilia, Volume 32, Issue 2, Page 371-380, March/April 2026.
ABSTRACT Introduction Haemophilia A in paediatric patients presents a lifelong risk of spontaneous and trauma‐induced haemorrhage, leading to progressive joint damage, disability and impaired quality of life. Emicizumab, a bispecific monoclonal antibody administered subcutaneously, offers sustained haemostatic protection and has shown promising ...
Konstantina Bolou, George Triantafyllou, Athina Dettoraki, Aikaterini Michalopoulou, Miltiades Kyprianou, Olympia Papakonstantinou, Helen Pergantou   +6 more
wiley   +1 more source

A novel bispecific antibody targeting TNF-α and IL-6 receptor as a potent immunotherapeutic agent for inflammation. [PDF]

Appl Microbiol Biotechnol
Heravi M, Damough S, Mafakher L, Talebkhan Y, Nematollahi L, Ghazizadeh L, Ajdari S.   +6 more
europepmc   +1 more source

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry

Haemophilia, Volume 32, Issue 2, Page 534-542, March/April 2026.
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen, Anthony K. C. Chan, Davide Matino, Emma Iserman, Arun Keepanasseril, Karen Strike   +5 more
wiley   +1 more source

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma. [PDF]

Blood Cancer J
Ng LCK, Lee XH, Tan YC, Wong KL, Chow JCY, Ling VWT, Thong EWS, Chan EHL, Chan WL, Samuel M, Poon MLM.   +10 more
europepmc   +1 more source

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 377-386, March 2026.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Physicochemical and biological characterization of a bispecific antibody in a CrossMab/KIH format that targets EGFR and VEGF-A. [PDF]

Front Immunol
Ayinde S, Dutta S, Mohan N, Wu WJ.
europepmc   +1 more source